This company offers a diagnostic platform that analyzes cell-free DNA methylation profiles from blood samples to detect cancer, select therapies, and monitor treatment. Their platform combines sequencing technology and computational methods to provide comprehensive genome coverage, enabling affordable and non-invasive cancer management.
Funding
Funding not disclosed
Founders
Product
Problem
Early cancer detection using cell-free DNA (cfDNA) is challenging due to the low fraction of tumor DNA, the molecular heterogeneity of cancer, and limited sample sizes. Current methods often lack the sensitivity and accuracy needed for reliable early-stage diagnosis and tissue-of-origin identification.
Solution
EarlyDiagnostics (EarlyDx) offers a platform for early cancer detection and precision medicine through non-invasive liquid biopsy tests. Their CancerRadar test utilizes cfMethyl-Seq, a cost-effective next-generation sequencing (NGS) assay for genome-wide methylation profiling of cfDNA, providing enhanced enrichment in CpG islands compared to whole-genome bisulfite sequencing. The platform incorporates a computational component that extracts methylation information from cfMethyl-Seq data to diagnose cancer and identify its tissue of origin. EarlyDx also provides EarlyDx-Cloud, a bioinformatics solution for liquid biopsy analysis, and partners with biopharmaceutical companies for biomarker discovery, translational research, and companion diagnostics development.
Target Audience
The primary target audience includes diagnostic companies, biopharmaceutical companies, and research institutions involved in cancer research, drug development, and clinical diagnostics.
Features
- CancerRadar test for early cancer detection and tissue-of-origin localization
- cfMethyl-Seq technology for genome-wide methylation profiling of cfDNA
- cfSNV: Computational tool for mutation calling from blood samples
- cfTrack: Non-invasive monitoring of cancer MRD, recurrence, and evolution
- EarlyDx-Cloud: Bioinformatics platform for liquid biopsy data analysis
- Integrated cancer detection system addressing challenges of low tumor DNA fraction and molecular heterogeneity
- AI-based computational algorithms for biomarker discovery and validation
- Services for tumor mutation burden (TMB) assessment, microsatellite instability (MSI) analysis, HLA-typing, and neoantigen identification